NASDAQ:IMMY - Imprimis Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.45 +0.14 (+6.06 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$2.31
Today's Range$2.25 - $2.45
52-Week Range$1.35 - $3.45
Volume44,000 shs
Average Volume292,708 shs
Market Capitalization$50.11 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.45
Imprimis Pharmaceuticals logoImprimis Pharmaceuticals, Inc., an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive IMMY News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMMY
CUSIPN/A
Phone858-704-4040

Debt

Debt-to-Equity Ratio180.00
Current Ratio1.25
Quick Ratio0.91

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.77 million
Price / Sales1.91
Cash FlowN/A
Price / CashN/A
Book Value$0.13 per share
Price / Book18.85

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-11,980,000.00
Net Margins-35.52%
Return on Equity-298.28%
Return on Assets-42.44%

Miscellaneous

Employees128
Outstanding Shares20,880,000

Imprimis Pharmaceuticals (NASDAQ:IMMY) Frequently Asked Questions

What is Imprimis Pharmaceuticals' stock symbol?

Imprimis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMMY."

How were Imprimis Pharmaceuticals' earnings last quarter?

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) issued its earnings results on Tuesday, May, 15th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $8.87 million during the quarter. Imprimis Pharmaceuticals had a negative net margin of 35.52% and a negative return on equity of 298.28%. View Imprimis Pharmaceuticals' Earnings History.

When is Imprimis Pharmaceuticals' next earnings date?

Imprimis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Imprimis Pharmaceuticals.

Who are some of Imprimis Pharmaceuticals' key competitors?

Who are Imprimis Pharmaceuticals' key executives?

Imprimis Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark L. Baum, Founder, CEO & Director (Age 45)
  • Mr. Andrew R. Boll CFA, CMA, CFO & Corp. Sec. (Age 36)
  • Mr. John P. Saharek, Chief Commercial Officer (Age 58)
  • Mr. David Moufarrège, VP of Technology
  • Mr. Pramod Sharma Ph.D., VP of Quality

Has Imprimis Pharmaceuticals been receiving favorable news coverage?

News headlines about IMMY stock have trended positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Imprimis Pharmaceuticals earned a news impact score of 0.37 on Accern's scale. They also gave press coverage about the specialty pharmaceutical company an impact score of 46.89 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Imprimis Pharmaceuticals' major shareholders?

Imprimis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Institutional & Family Asset Management LLC (0.63%), Granite Investment Partners LLC (0.32%) and Northern Trust Corp (0.32%). Company insiders that own Imprimis Pharmaceuticals stock include Andrew R Boll, Mark L Baum, Richard L Md Lindstrom and Robert J Kammer. View Institutional Ownership Trends for Imprimis Pharmaceuticals.

Which institutional investors are selling Imprimis Pharmaceuticals stock?

IMMY stock was sold by a variety of institutional investors in the last quarter, including Institutional & Family Asset Management LLC and Granite Investment Partners LLC. View Insider Buying and Selling for Imprimis Pharmaceuticals.

Which institutional investors are buying Imprimis Pharmaceuticals stock?

IMMY stock was bought by a variety of institutional investors in the last quarter, including Northern Trust Corp. Company insiders that have bought Imprimis Pharmaceuticals stock in the last two years include Andrew R Boll, Mark L Baum and Richard L Md Lindstrom. View Insider Buying and Selling for Imprimis Pharmaceuticals.

How do I buy shares of Imprimis Pharmaceuticals?

Shares of IMMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Imprimis Pharmaceuticals' stock price today?

One share of IMMY stock can currently be purchased for approximately $2.45.

How big of a company is Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals has a market capitalization of $50.11 million and generates $26.77 million in revenue each year. Imprimis Pharmaceuticals employs 128 workers across the globe.

How can I contact Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals' mailing address is 12264 El Camino Real Suite 350, San Diego CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-704-4040 or via email at [email protected]


MarketBeat Community Rating for Imprimis Pharmaceuticals (IMMY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about Imprimis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.